WILMINGTON – Pharmaceutical giant AstraZeneca has acquired Caelum Biosciences, a small clinical-stage biotechnology company, for $150 million. The New Jersey-based Caelum was founded by New York-based biopharma company Fortress Biotech in 2017 to develop a ...